Research programme: heat shock protein-viral antigen fusions - Akela Pharma

Drug Profile

Research programme: heat shock protein-viral antigen fusions - Akela Pharma

Alternative Names: Hsp 6/11

Latest Information Update: 18 Mar 2013

Price : $50

At a glance

  • Originator Nventa Biopharmaceuticals Corporation
  • Developer Akela Pharma
  • Class Antigens; Heat shock proteins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C; Herpes simplex virus infections; HIV infections; Human papillomavirus infections

Most Recent Events

  • 14 Mar 2013 Akela Pharma and its subsidiaries cease operations
  • 12 Mar 2013 Discontinued - Preclinical for Human papillomavirus infections in USA (Parenteral)
  • 12 Mar 2013 Discontinued - Preclinical for Herpes simplex virus infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top